Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CSTL
Castle Biosciences, Inc. Common Stock
stock NASDAQ

At Close
Aug 5, 2026 3:59:56 PM EDT
30.40USD-2.502%(-0.78)520,194
26.29Bid   36.31Ask   10.02Spread
Pre-market
0.00USD-100.000%(-30.39)0
After-hours
Aug 4, 2026 4:00:30 PM EDT
31.18USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 13, 2022
05:04PM EST  Castle Biosciences Highlights Recently-Published Data Confirming DecisionDx Is Independent Risk-Stratification Tool In Patients With Squamous Cell Carcinoma   Benzinga
Jan 10, 2022
07:28AM EST  Castle Biosciences Sees FY21 Sales To Meet Or Exceed Top End Of Guided Range Of $89M-93M   Benzinga
Jan 7, 2022
01:07PM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022   Benzinga
01:01PM EST  Stephens & Co. Initiates Coverage On Castle Biosciences with Overweight Rating, Announces Price Target of $59   Benzinga
Nov 19, 2021
07:09AM EST  UPDATE: Castle Says 'Data demonstrated that patients with a DecisionDx-Melanoma Class 1A (low risk) test result had a five-year recurrence-free survival rate and distant metastasis-free survival rate of 95.8% and 99.2%, respectively'   Benzinga
07:08AM EST  Castle Biosciences Highlights Data On DecisionsDx-Melanoma Published In 'Future Oncology'   Benzinga
Nov 9, 2021
12:03PM EST  SVB Leerink Maintains Outperform on Castle Biosciences, Lowers Price Target to $75   Benzinga
11:09AM EST  Castle Biosciences Q3 EPS $(0.47) Misses $(0.40) Estimate, Sales $23.48M Beat $22.97M Estimate   Benzinga
Nov 8, 2021
05:06AM EST  Earnings Scheduled For November 8, 2021   Benzinga
Oct 26, 2021
08:27AM EDT  Castle Biosciences Highlights New Data Further Validating Performance Of Co.'s DecisionDx DiffDx -Melanoma Test   Benzinga
Oct 25, 2021
08:31AM EDT  Castle Biosciences Reports Will Be Acquired By Pittsburgh Life Science Greenhouse, No Terms Disclosed   Benzinga
08:30AM EDT  Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company   PR Newswire
Oct 22, 2021
07:05AM EDT  Castle Biosciences Highlights Presentation Of Data From Suite Of Dermatologic Cancer Genomic Tests At Fall Clinical Dermatology Conference 2021 Oct. 21-24   Benzinga
Sep 28, 2021
07:19AM EDT  Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week Oct. 6   Benzinga
Sep 16, 2021
11:35AM EDT  Castle Biosciences's Return On Capital Employed Overview   Benzinga
07:04AM EDT  Castle Biosciences Announces New York Approval For Its DecisionDx DiffDx-Melanoma Test   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
07:10AM EDT  Castle Biosciences Awarded US Federal Supply Schedule Contract For DecisionDx-Melanoma; Size Not Disclosed   Benzinga
Aug 16, 2021
07:09AM EDT  Castle Biosciences Presents New Data on DecisionDx-Melanoma and DecisionDx-SCC at the 2021 American Academy of Dermatology Summer Meeting   Benzinga
Aug 10, 2021
05:42PM EDT  Castle Biosciences Q2 Earnings Edges Out Expectation On Record Test Report Volume   Benzinga
Aug 9, 2021
04:11PM EDT  Castle Biosciences Raises FY21 Sales Guidance From $80M-$83M To $89M-$93M vs $83.64M Est.   Benzinga
04:10PM EDT  Castle Biosciences Q2 EPS $(0.35) Beats $(0.37) Estimate, Sales $22.80M Beat $18.93M Estimate   Benzinga
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
04:11AM EDT  Earnings Scheduled For August 9, 2021   Benzinga
Aug 8, 2021
10:11AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 5, 2021
07:26AM EDT  Castle Biosciences Presents Data on DecisionDx-Melanoma and DecisionDx-SCC at the DERM2021 NP/PA CME Conference   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
07:06AM EDT  Castle Biosciences Highlights Presentation Of New Data Demonstrating DecisionDx-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck   Benzinga
Jul 22, 2021
05:01PM EDT  Castle Biosciences Presents Data on DecisionDx-Melanoma and DecisionDx-SCC at SDPA Annual Summer Dermatology Conference 2021   Benzinga
Jul 14, 2021
07:46AM EDT  SVB Leerink Maintains Outperform on Castle Biosciences, Raises Price Target to $85   Benzinga
Jun 24, 2021
09:50AM EDT  Return On Capital Employed Overview: Castle Biosciences   Benzinga
Jun 8, 2021
11:37AM EDT  Looking Into Castle Biosciences's Return On Capital Employed   Benzinga
May 26, 2021
12:42PM EDT  AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of   PR Newswire
May 21, 2021
07:02AM EDT  Castle Biosciences Reports Collaboration With American Skin Association To Provide 2021 Research Grant In Area Of Melanoma   Benzinga
May 20, 2021
07:09AM EDT  Castle Biosciences Announces Publication Describing The Findings Of A Squamous Cell Carcinoma Gene Expression Profiling Expert Panel In The Journal Of Drugs In Dermatology   Benzinga
May 10, 2021
05:11PM EDT  Castle Biosciences Highlights Pipeline Initiative To Develop A Genomic Test Aimed At Predicting Systemic Therapy Response In Patients With Moderate To Severe Psoriasis, Atopic Dermatitis, Related Conditions   Benzinga
04:57PM EDT  Castle Biosciences: Q1 Earnings Insights   Benzinga
04:18PM EDT  Castle Biosciences Sees FY21 Sales $80M-$83M vs $79.84M Est.   Benzinga
04:18PM EDT  Castle Biosciences Q1 EPS $(0.17) Beats $(0.24) Estimate, Sales $22.80M Beat $16.66M Estimate   Benzinga
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 5, 2021
07:12AM EDT  Castle Biosciences Highlights Presentation Of DecisionDx-UM Test Data At Association For Research In Vision And Ophthalmology 2021   Benzinga
Apr 30, 2021
12:16PM EDT  Lake Street Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $94   Benzinga
Apr 27, 2021
07:21AM EDT  UPDATE: Myriad Genetics Signs Definitive Agreement To Sell Myriad myPath Melanoma Laboratory To Castle Biosciences For $32.5M In Cash   Benzinga
07:20AM EDT  Castle Biosciences Signs Definitive Agreement To Acquire Myriad myPath Laboratory For $32.5M   Benzinga
07:08AM EDT  Myriad Genetics To Sell Myriad MyPath Melanoma, LLC, Laboratory   RTTNews
Apr 23, 2021
07:03AM EDT  Castle Biosciences To Present Data Showing DecisionDx-Melanoma as Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population   Benzinga
Apr 16, 2021
07:02AM EDT  Castle Biosciences Highlights Presentation At 10th World Congress Of Melanoma And 17th European Association Of Dermato-Oncology Congress   Benzinga
Apr 15, 2021
07:06AM EDT  Castle Biosciences Highlights Presentation Of New Independent Validation Study Of i31-GEP Artificial Intelligence Algorithm   Benzinga
Apr 14, 2021
07:15AM EDT  Castle Biosciences Highlights Publication Of DecisionDx-Melanoma Data In American Journal of Surgery   Benzinga
Apr 13, 2021
07:13AM EDT  Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma   Benzinga
Mar 25, 2021
05:01PM EDT  Castle Biosciences Announces Publication It Says Demonstrates Dermatologists Are 'Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions'   Benzinga
Mar 9, 2021
09:17AM EST  The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data   Benzinga
Mar 8, 2021
04:43PM EST  Castle Biosciences: Q4 Earnings Insights   Benzinga
04:07PM EST  Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk   Benzinga
04:07PM EST  Castle Biosciences Q4 EPS $(0.23) Misses $(0.12) Estimate, Sales $17.30M Beat $15.74M Estimate   Benzinga
04:05AM EST  Earnings Scheduled For March 8, 2021   Benzinga
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
07:07AM EST  Castle Biosciences Says Presents New Data On Validity, Accuracy Of DecisionDx-Melanoma In Patients With T1 Cutaneous Melanoma Tumors At 19th Annual South Beach Symposium   Benzinga
Feb 3, 2021
05:29AM EST  KeyBanc Maintains Overweight on Castle Biosciences, Raises Price Target to $90   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 15, 2021
10:48AM EST  Castle Biosciences shares were trading higher after SVB Leerink maintained an Outperform rating on the stock and raised its price target from $70 to $80.   Benzinga
05:39AM EST  SVB Leerink Maintains Outperform on Castle Biosciences, Raises Price Target to $80   Benzinga
Jan 13, 2021
07:06AM EST  Castle Biosciences Reports 18,185 Gene Expression Profile Tests Were Delivered In 2020; Announces Co. Launched Two New Skin Cancer Tests In 2H2020, Increasing Estimated In-Market U.S. Total Adressable Market To $2B   Benzinga
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
07:02AM EST  Castle Biosciences Announces Early Repayment Of Debt   Benzinga
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 17, 2020
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
04:46PM EST  Castle Biosciences Reports $125M Common Stock Offering   Benzinga
04:42PM EST  Castle Biosciences Filing Shows Registration For Mixed Securities Shelf Offering, No Size Disclosed   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
06:24AM EST  SVB Leerink Maintains Outperform on Castle Biosciences, Raises Price Target to $70   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 4, 2020
07:02AM EST  Castle Biosciences Highlights Publication Of Peer-Reviewed Publication Demonstrating Clinical Impact Of DecisionDx-Melanoma   Benzinga
Nov 9, 2020
04:19PM EST  Castle Biosciences Q3 EPS $(0.23) Misses $(0.11) Estimate, Sales $15.22M Beat $14.99M Estimate   Benzinga
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 2, 2020
07:04AM EST  Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma; DecisionDx DiffDx-Melanoma Is Designed For Use In Patients With Suspicious Pigmented Lesions   Benzinga
Oct 8, 2020
07:46AM EDT  Castle Biosciences Announces Expanded Medicare Coverage For DecisionDx-Melanoma In Cutaneous Melanoma   Benzinga
Sep 25, 2020
08:14AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
07:01AM EDT  SVB Leerink Maintains Outperform on Castle Biosciences, Raises Price Target to $57   Benzinga
Sep 4, 2020
07:00AM EDT  Castle Biosciences to Present at the Baird 2020 Global Healthcare Conference   Business Wire
Sep 2, 2020
05:48PM EDT  Castle Biosciences Announces Commercial Launch of DecisionDx-SCC   Business Wire
Sep 1, 2020
05:01PM EDT  Castle Biosciences Announces New CCO, COO, New Medical Director   Benzinga
05:00PM EDT  Castle Biosciences Announces Leadership Promotions and New Medical Director   Business Wire
Aug 30, 2020
08:24AM EDT  The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing   Benzinga
Aug 26, 2020
05:00PM EDT  Castle Biosciences to Hold Webcast Highlighting Commercial Launch of DecisionDx-SCC   Business Wire
Aug 11, 2020
05:01AM EDT  SVB Leerink Maintains Outperform on Castle Biosciences, Raises Price Target to $50   Benzinga
Aug 10, 2020
04:20PM EDT  Castle Biosciences Q2 EPS $(0.08) Beats $(0.40) Estimate, Sales $12.70M Up From $10.74M YoY   Benzinga
04:05PM EDT  Castle Biosciences Announces Second Quarter 2020 Results   Business Wire
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 5, 2020
07:01AM EDT  Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference   Business Wire
Jul 27, 2020
07:00AM EDT  Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020   Business Wire
Jul 15, 2020
08:42AM EDT  Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC